Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081013 | 0.80 | MAOA (0.42) | KMT2AMEN1OPRM1OPRD1OPRK1 | |
| SCHEMBL20012538 | 0.78 | OPRM1 (0.40) | KMT2AMEN1OPRM1OPRD1OPRK1 | |
| SCHEMBL18038697 | 0.77 | GRIN2B (0.44) | OPRM1OPRL1CYP46A1GRIN2BALDH1A1 | |
| SCHEMBL14000290 | 0.76 | CYP46A1 (0.45) | OPRM1OPRD1OPRK1OPRL1CYP46A1 | |
| SCHEMBL20008961 | 0.76 | OPRL1 (0.61) | CYP2D6KMT2AMEN1OPRM1OPRD1 | |
| SCHEMBL17542448 | 0.76 | OPRM1 (0.50) | CYP2D6OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20147375 | 0.73 | MEN1 (0.52) | CYP2D6KMT2AMEN1OPRM1OPRD1 | |
| SCHEMBL24634098 | 0.73 | SLC6A2 (0.40) | CYP2D6 | |
| SCHEMBL13957387 | 0.72 | OPRM1 (0.43) | CYP2D6KMT2AMEN1OPRM1OPRD1 | |
| SCHEMBL16601016 | 0.72 | MAOA (0.45) | OPRM1OPRK1OPRL1CYP46A1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | CYP2D6 4116/4885KMT2A 489/4885MEN1 1824/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | CYP2D6 4116/4885KMT2A 489/4885MEN1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.